lorigerlimab

{
  "id": "MLC-T-ONC-014885",
  "term": "lorigerlimab",
  "field": "Oncology and biomedicine",
  "definition": "A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.",
  "synonyms": [
    "dual-affinity retargeting protein MGD019",
    "PD-1 x CTLA4 bispecific DART molecule MGD019",
    "PD-1 x CTLA4 DART protein MGD019",
    "bispecific DART protein MGD019",
    "anti-PD-1/anti-CTLA4 DART protein MGD019",
    "D-1 x CTLA4 DART protein MGD019"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lorigerlimab/"
}